VBC101 F11
Alternative Names: VBC-101; VBC101-F11Latest Information Update: 13 Nov 2025
At a glance
- Originator VelaVigo (Shanghai) Limited
- Class Antineoplastics; Auristatins; Bispecific antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Mitosis inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 23 Sep 2025 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (Parenteral) (NCT07136779)
- 22 Aug 2025 VelaVigo Bio plans a phase I/IIa trial for Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (Parenteral) in September 2025 (NCT07136779)
- 05 Apr 2024 Preclinical trials in Solid tumours in China (Parenteral)